Core Viewpoint - Peijia Medical (09996) is experiencing a stock price increase, with a current rise of 2.6% to HKD 5.92, and a trading volume of HKD 8.93 million. The company announced that its CEO, Dr. Zhang Yi, will begin purchasing company shares in the open market starting December 1, 2025, with a total investment not exceeding HKD 15 million. This move indicates potential confidence in the company's future performance and growth prospects [1][1][1]. Group 1 - Peijia Medical's CEO, Dr. Zhang Yi, plans to buy company shares in the open market starting December 1, 2025, with an investment cap of HKD 15 million [1][1][1]. - The company's stock has risen over 3%, currently at HKD 5.92, with a trading volume of HKD 8.93 million [1][1][1]. Group 2 - CITIC Securities has reported that Peijia Medical's TAVR products are experiencing continuous growth in volume and steadily increasing market share [1][1][1]. - The GeminiOneTEER system, TaurusTrio aortic regurgitation valve, and TaurusNXT dry valve TAVR are expected to receive intensive approvals between the end of 2025 and 2026, which will drive accelerated growth in the valve business [1][1][1]. - The MonarQ tricuspid valve system has initiated global clinical trials, and the company has secured external financing for its cutting-edge technology, indicating a clear path for innovation and international expansion [1][1][1].

Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 112.65 and a sector rating of "Outperform" [2][4]. Core Insights - The company has demonstrated rapid growth, with a projected revenue of RMB 502 million for 2024, representing a year-on-year increase of 35.41%. The net profit attributable to the parent company is expected to reach RMB 146 million, up 27.02% year-on-year. The fourth quarter of 2024 saw a significant revenue increase of 85.04% year-on-year, with a net profit growth of 95.35% [4][6]. - The company is expected to maintain strong growth in the coming years, driven by the gradual launch of new products. The forecasted net profits for 2025, 2026, and 2027 are RMB 235 million, RMB 326 million, and RMB 451 million, respectively, with corresponding EPS of RMB 1.71, RMB 2.38, and RMB 3.28 [4][6]. - The company has a robust product pipeline, with several new products expected to receive approval soon, which will further accelerate growth. The R&D expenses for 2024 are projected to be RMB 151 million, accounting for 30.17% of revenue, indicating a strong commitment to innovation [4][9]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of RMB 5.02 billion, a 35.41% increase year-on-year, and a net profit of RMB 1.46 billion, up 27.02%. The Q1 2025 revenue is projected at RMB 1.00 billion, reflecting a 31.30% increase year-on-year, with net profit soaring by 290.69% [4][8]. Valuation - The adjusted profit forecasts for 2025-2027 are RMB 2.35 billion, RMB 3.26 billion, and RMB 4.51 billion, respectively. The corresponding PE ratios are projected to be 65.8, 47.4, and 34.3 times [6][8]. Market Position - The company has established a strong position in the valve market, with significant growth in its heart valve replacement and repair segment, which saw a 64.28% increase in revenue. The approval of the TAVR product is expected to further enhance the company's market presence [9].